Matches in SemOpenAlex for { <https://semopenalex.org/work/W2319328441> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2319328441 abstract "Over sixty percent of patients with melanoma have the activating B-RAFV600E mutation leading to increased activation of the mitogen activated protein kinase (MAPK) pathway. The downstream effects of MAPK pathway activation are increased proliferation, invasiveness, and survival through the regulation of down-stream targets such as the pro-apoptotic protein BIM. Prior studies have shown that inhibiting MAPK kinase (MEK), downstream of constitutively active B-RAF, can up-regulate BIM, leading to increased apoptosis in melanoma cell lines. However, single agent MEK inhibition has had limited effectiveness in the clinical setting for late-stage melanoma patients, likely due to an inadequate induction of apoptosis. We hypothesized that combining the clinically relevant MEK inhibitor, AZD6244 (ARRY142886) with a BCL-2 inhibitor, ABT-737, would lead to increased apoptosis over single agent therapies in melanoma cells via BIM activation and pan-BCL-2 inhibition. We compared single treatments of AZD6244 and ABT737 to the combination of these agents in a panel of melanoma tumor cell lines chosen by mutational status in both a monolayer system and an anchorage independent system. The combination of AZD6244 and ABT-737 had a synergistic effect on decreasing cell viability and increasing apoptosis compared to single agent treatments regardless of B-RAF mutational status. Western blotting revealed dramatic increases in cleaved caspase 3 and PARP with combinational treatment compared to single agent therapy. These early pre-clinical experiments indicate that AZD6244 combined with ABT-737 may be an effective combination therapy for patients with late-stage melanoma. Currently, we have plans to conduct in vivo studies to translate these results into the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A28." @default.
- W2319328441 created "2016-06-24" @default.
- W2319328441 creator A5026042020 @default.
- W2319328441 creator A5038033108 @default.
- W2319328441 creator A5046649612 @default.
- W2319328441 creator A5047686363 @default.
- W2319328441 creator A5053602981 @default.
- W2319328441 creator A5062982351 @default.
- W2319328441 creator A5074135831 @default.
- W2319328441 date "2011-11-12" @default.
- W2319328441 modified "2023-09-27" @default.
- W2319328441 title "Abstract A28: Apoptosis induction with the MEK inhibitor AZD6244 and BH3 mimetic ABT-737 in melanoma." @default.
- W2319328441 doi "https://doi.org/10.1158/1535-7163.targ-11-a28" @default.
- W2319328441 hasPublicationYear "2011" @default.
- W2319328441 type Work @default.
- W2319328441 sameAs 2319328441 @default.
- W2319328441 citedByCount "0" @default.
- W2319328441 crossrefType "proceedings-article" @default.
- W2319328441 hasAuthorship W2319328441A5026042020 @default.
- W2319328441 hasAuthorship W2319328441A5038033108 @default.
- W2319328441 hasAuthorship W2319328441A5046649612 @default.
- W2319328441 hasAuthorship W2319328441A5047686363 @default.
- W2319328441 hasAuthorship W2319328441A5053602981 @default.
- W2319328441 hasAuthorship W2319328441A5062982351 @default.
- W2319328441 hasAuthorship W2319328441A5074135831 @default.
- W2319328441 hasConcept C184235292 @default.
- W2319328441 hasConcept C190283241 @default.
- W2319328441 hasConcept C2777658100 @default.
- W2319328441 hasConcept C2781249067 @default.
- W2319328441 hasConcept C502942594 @default.
- W2319328441 hasConcept C55493867 @default.
- W2319328441 hasConcept C57074206 @default.
- W2319328441 hasConcept C86803240 @default.
- W2319328441 hasConcept C95444343 @default.
- W2319328441 hasConcept C97029542 @default.
- W2319328441 hasConcept C98274493 @default.
- W2319328441 hasConceptScore W2319328441C184235292 @default.
- W2319328441 hasConceptScore W2319328441C190283241 @default.
- W2319328441 hasConceptScore W2319328441C2777658100 @default.
- W2319328441 hasConceptScore W2319328441C2781249067 @default.
- W2319328441 hasConceptScore W2319328441C502942594 @default.
- W2319328441 hasConceptScore W2319328441C55493867 @default.
- W2319328441 hasConceptScore W2319328441C57074206 @default.
- W2319328441 hasConceptScore W2319328441C86803240 @default.
- W2319328441 hasConceptScore W2319328441C95444343 @default.
- W2319328441 hasConceptScore W2319328441C97029542 @default.
- W2319328441 hasConceptScore W2319328441C98274493 @default.
- W2319328441 hasLocation W23193284411 @default.
- W2319328441 hasOpenAccess W2319328441 @default.
- W2319328441 hasPrimaryLocation W23193284411 @default.
- W2319328441 hasRelatedWork W1543856063 @default.
- W2319328441 hasRelatedWork W1626821504 @default.
- W2319328441 hasRelatedWork W1772974181 @default.
- W2319328441 hasRelatedWork W1974599057 @default.
- W2319328441 hasRelatedWork W1983915589 @default.
- W2319328441 hasRelatedWork W1986115996 @default.
- W2319328441 hasRelatedWork W2004186722 @default.
- W2319328441 hasRelatedWork W2044602856 @default.
- W2319328441 hasRelatedWork W2055869270 @default.
- W2319328441 hasRelatedWork W2067956232 @default.
- W2319328441 hasRelatedWork W2099604307 @default.
- W2319328441 hasRelatedWork W2129337940 @default.
- W2319328441 hasRelatedWork W2209297786 @default.
- W2319328441 hasRelatedWork W2316080015 @default.
- W2319328441 hasRelatedWork W2318778072 @default.
- W2319328441 hasRelatedWork W2487850446 @default.
- W2319328441 hasRelatedWork W2739786760 @default.
- W2319328441 hasRelatedWork W2740464310 @default.
- W2319328441 hasRelatedWork W2887865014 @default.
- W2319328441 hasRelatedWork W2922376834 @default.
- W2319328441 isParatext "false" @default.
- W2319328441 isRetracted "false" @default.
- W2319328441 magId "2319328441" @default.
- W2319328441 workType "article" @default.